Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected relative price increase of over 20% in the next six months [14]. Core Insights - The company has returned to a growth trajectory, with a significant increase in revenue and profit margins. The revenue for 2025 is projected at 82.1 billion CNY, reflecting a growth rate of 9.95% [8][10]. - The company has successfully diversified its product portfolio, with a notable increase in sales from its skin health line, which grew by 73.2% in 2025 [8]. - The company plans to spin off its skin health business, Demy Pharmaceuticals, for independent listing on the Hong Kong Stock Exchange, which is expected to enhance its market position [8]. Financial Projections - Revenue projections for 2026, 2027, and 2028 are 94.9 billion CNY, 114.1 billion CNY, and 137.3 billion CNY, respectively, with growth rates of 15.59%, 20.20%, and 20.30% [3][10]. - The net profit attributable to the parent company is expected to reach 1.97 billion CNY in 2026, with a growth rate of 32.20% [3][10]. - Earnings per share (EPS) is projected to increase from 0.61 CNY in 2025 to 1.16 CNY by 2028 [3][10]. Revenue Breakdown - The revenue from the cardiovascular segment is expected to grow significantly, reaching 40.4 billion CNY in 2026, with a growth rate of 35% [9][10]. - The digestive and autoimmune segment is also projected to grow by 35% in 2026, reaching 40.1 billion CNY [9][10]. - The ophthalmology segment is expected to see a growth rate of 30%, reaching 9.2 billion CNY in 2026 [9][10]. Product Development - The company has launched two innovative drugs in 2025 and has six more in the NDA review stage, indicating a strong pipeline for future growth [8]. - The proportion of exclusive and innovative products in the revenue mix has increased to 59.8%, highlighting the company's focus on high-growth areas [8].

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The global biopharmaceutical industry is experiencing a surge in capital market activities, with numerous collaborations and financing deals taking place, indicating a robust investment environment [4][16] - Significant clinical advancements are reported in various therapeutic areas, including metabolic diseases, oncology, and immunology, showcasing the industry's innovation potential [5][8] - The trend of accelerating capitalizations and upgrading research and development models is evident, with companies increasingly focusing on AI-driven drug development and advanced therapeutic modalities [5][16] Summary by Sections Global Biopharmaceutical Industry Dynamics - The report highlights a series of strategic collaborations and financing activities, including Yuan Yi Bio's acquisition of CNS drug RAP-219 rights for up to $328 million and GSK's sale of linerixibat global rights for up to $690 million [4][16] - Merck's termination of its collaboration with Hengrui for the global rights to HRS-1167, originally valued at €1.4 billion, reflects a trend of prioritizing high-potential projects [4][16] Major Events in the Global Biopharmaceutical Industry - Vertex's Povetacicept shows promising results in treating IgA nephropathy, with a 49.8% reduction in 24-hour urine protein creatinine compared to placebo [9] - GSK's licensing agreement with Alfasigma for linerixibat includes a $300 million upfront payment and potential milestone payments totaling up to $690 million [6][16] Important Clinical Developments - Vertex's Povetacicept demonstrates significant clinical efficacy in a Phase III trial, indicating a potential shift in treatment paradigms for IgA nephropathy [9] - New clinical data from various companies, such as Ultragenyx's Avalotcagene ontaparvovec, shows a 18% reduction in plasma ammonia levels in patients with ornithine transcarbamylase deficiency [10][12] Investment and Transaction Events - The report details multiple financing rounds, including over $100 million raised by Aikang Bio in Series A3 funding, and nearly $100 million raised by Yili Pharma [17][20] - The strategic collaboration between Huazhong Pharmaceutical and Roche aims to enhance the commercialization of T-DM1 in mainland China, leveraging both companies' strengths [26] Regulatory Dynamics - The report notes significant regulatory approvals in China, including the approval of innovative drugs for chronic kidney disease and vitiligo, indicating a supportive regulatory environment for new therapies [29][30] - The FDA has streamlined the development process for biosimilars, which may enhance the market entry of new products and improve patient access [34][35]

Group 1 - The Hong Kong pharmaceutical sector is experiencing a rebound, with the Hong Kong Stock Connect Innovation Drug ETF (159570) rising nearly 2% and achieving a trading volume exceeding 2.05 billion yuan, leading its peers with a total scale of over 22.8 billion yuan [1] - The 2026 European Association of Urology (EAU) annual meeting held in London showcased innovative applications of HER2-targeted antibody-drug conjugates (ADCs) in treating urothelial carcinoma, with multiple cutting-edge research results from China presented [3] - Rongchang Biopharmaceutical recently reported a revenue of 3.251 billion yuan, a year-on-year increase of 89.36%, and a net profit of 709 million yuan, marking a turnaround from losses, primarily driven by increased sales of its injectable drugs [3] Group 2 - The Hong Kong Stock Connect Innovation Drug ETF (159570) saw most of its constituent stocks perform positively, with Rongchang Biopharmaceutical up over 6%, Kangzhi Pharmaceutical up over 5%, and China Biopharmaceutical up over 3% [3] - Recent approvals for new drugs and indications in China include: 1) Hengrui Medicine's oral new drug for a new indication; 2) Roche's CD79B ADC new indication approved in China; 3) Kangzhi Pharmaceutical's new drug for renal anemia approved; 4) Junshi Biosciences' first domestic PD-1 subcutaneous formulation submitted for approval [6] - The innovative drug sector in China is transitioning from "fast following" to "innovation leading," with significant advancements in new technology platforms such as molecular glue, small nucleic acids, and in vivo CART, which are expected to enhance drug development efficiency and cost-effectiveness [7][8][9] Group 3 - The recent policy shift designating the biopharmaceutical industry as an emerging pillar industry is expected to release a series of policy dividends, indicating a positive outlook for the sector [11] - The Hong Kong Stock Connect Innovation Drug ETF (159570) is fully invested in innovative drugs, with the top ten constituent stocks accounting for 73.54% of its weight, highlighting its focus on the innovation drug sector [12]

香港交易及結算所有限公司、香港聯合交易所有限公司及新加坡證券交易所有限公司對 本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並表明概不就因本公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CKD患者腎功能逐漸喪失，最終出現腎衰竭。健康的腎臟會自然分泌促紅細胞生成素 (EPO) ，這種激素可促進紅細胞生成。如果腎功能受損，腎臟生成EPO水平下降或完全 不生成EPO，從而導致貧血。HIF-PHI通過增加內源性促紅細胞生成素的生成、改善鐵的 利用率和降低鐵調素的水平來促進紅細胞生成。產品中國III期臨床試驗取得了積極結 果。主要研究終點血紅蛋白（Hb）水平（第7-9周Hb平均值相對於基線的變化）結果顯 示，試驗組優於安慰劑組。擴展期研究結果顯示，產品可使Hb水平長期維持在達標水平， 且安全性良好。此外，產品還可以顯著降低鐵調素水平，糾正鐵代謝紊亂。 據估計，中國有超過1.2億CKD患者。貧血是CKD常見併發症之一。國內一項調研顯示， CKD1～5 期患者貧血患病率依次為：22.0%、37.0%、45.4%、85.1%和98.2%。血液透析 CKD貧血患者的治療達標率（血紅蛋 ...

Core Viewpoint - Cangzhou Pharmaceutical (00867) is rated "Buy" by Cinda Securities, with projected revenue growth from 8.216 billion yuan in 2025 to 12.028 billion yuan in 2027, and net profit growth from 1.615 billion yuan to 2.238 billion yuan during the same period, indicating a positive long-term growth outlook for the company [1] Group 1: Company Overview - Cangzhou Pharmaceutical, founded in 1992, has transformed from a drug agency to an innovative comprehensive pharmaceutical enterprise, leading in domestic specialized commercialization [2] - The company faced revenue declines in 2023-2024 due to national centralized procurement policies, but is expected to recover in 2025 as the negative impacts are largely absorbed [2] Group 2: Commercialization and Market Strategy - The company has a robust commercialization capability with a professional academic promotion team of approximately 4,700 members, covering over 50,000 hospitals and medical institutions in China [3] - Cangzhou has established a comprehensive R&D, registration, commercialization, and production layout in the Southeast Asian market, creating a sustainable second growth curve [3] Group 3: Business Segments - The company operates four main business segments: 1. Cardiovascular diseases, accounting for about 48% of revenue, with recovery from centralized procurement impacts and rapid growth of innovative products [4] 2. Digestive and autoimmune diseases, contributing approximately 30% of revenue, supported by exclusive products and new innovations [4] 3. Skin health, representing about 11% of revenue, with significant potential from newly approved products and plans for separate listing [4] 4. Ophthalmology, making up around 8% of revenue, with competitive product offerings including exclusive eye drops and new anti-VEGF drugs [4] Group 4: Innovation Pipeline - The company has nearly 40 innovative pipelines, with six innovative drugs already commercialized and several others in the NDA stage, indicating a fruitful innovation phase [5] - Key innovative products include treatments for acute ischemic stroke, chronic kidney disease anemia, rabies exposure, tetanus, Alzheimer's disease, and atopic dermatitis, with peak sales potential exceeding 10 billion yuan for core products [5]

Core Viewpoint - Cangzhou Pharmaceutical (00867) is rated "Buy" by Cinda Securities, with projected revenue growth from 2025 to 2027 at 10%, 20%, and 22% respectively, and net profit growth at 0%, 15%, and 21% respectively, indicating strong long-term growth potential for the company [1][2]. Group 1: Company Overview - Cangzhou Pharmaceutical, founded in 1992, has transformed from a drug agency to an innovative comprehensive pharmaceutical enterprise, positioning itself as a leading commercial player in the domestic market [2]. - The company faced revenue declines in 2023-2024 due to the impact of national centralized procurement policies, but is expected to recover in 2025 with stabilization in core businesses and rapid growth in emerging sectors [2]. Group 2: Commercialization and Market Strategy - The company boasts a robust commercialization capability with a professional team of approximately 4,700, covering over 50,000 hospitals and medical institutions in China, as well as around 300,000 retail pharmacies and major e-commerce platforms [3]. - Cangzhou has established a comprehensive R&D, registration, commercialization, and production layout in the Southeast Asian market, creating a sustainable second growth curve [3]. Group 3: Business Segments - The company operates four main business segments: 1. Cardiovascular diseases, accounting for about 48% of revenue, with recovery from procurement impacts and rapid growth of innovative products [4]. 2. Digestive and autoimmune diseases, contributing approximately 30% of revenue, supported by exclusive products and new innovations [4]. 3. Skin health, representing about 11% of revenue, with significant potential from newly approved products and plans for separate listing [4]. 4. Ophthalmology, making up around 8% of revenue, with competitive product offerings including exclusive eye drops and newly introduced anti-VEGF drugs [4]. Group 4: Innovation Pipeline - The company has developed nearly 40 innovative pipelines, entering a phase of significant results, with six innovative drugs already commercialized [5]. - Key products in the NDA stage include treatments for acute ischemic stroke, chronic kidney disease anemia, rabies exposure, tetanus, Alzheimer's disease, and atopic dermatitis, with peak sales potential exceeding 10 billion [5].

Core Viewpoint - The company, Kangzhe Pharmaceutical, is transitioning into a new growth cycle through innovation and transformation, despite facing revenue declines due to national procurement policies. The negative impacts are expected to be largely mitigated by mid-2025, with a return to positive growth in revenue and net profit [1][4]. Group 1: Business Performance - Kangzhe Pharmaceutical has established itself as a leading open pharmaceutical platform in China, with a comprehensive commercial capability covering over 50,000 hospitals and 300,000 retail pharmacies [1]. - The company’s four main business segments are performing collaboratively: 1. Cardiovascular diseases account for approximately 48% of revenue, with the impact of procurement policies nearly cleared [2]. 2. The digestive and autoimmune segment contributes about 30% of revenue, supported by exclusive products [2]. 3. The skin health segment, operated by a subsidiary, has significant potential with new products and plans for a separate listing [2]. 4. The ophthalmology segment, making up about 8% of revenue, has introduced competitive products to enhance growth [2]. Group 2: Innovation Pipeline - The company has developed nearly 40 innovative products, with six already commercialized. Key products in the NDA stage include treatments for stroke, chronic kidney disease, rabies exposure, tetanus, Alzheimer's disease, and atopic dermatitis, with peak sales potential exceeding 10 billion [3]. - Multiple self-developed innovative drugs are entering clinical stages, indicating a robust pipeline of diverse innovations [3]. Group 3: Financial Forecast - Revenue projections for 2025-2027 are estimated at 8.216 billion, 9.859 billion, and 12.028 billion, with year-on-year growth rates of 10%, 20%, and 22% respectively. Net profit forecasts are 1.615 billion, 1.850 billion, and 2.238 billion, with growth rates of 0%, 15%, and 21% [4]. - The company is viewed positively for its long-term growth potential, receiving a "buy" rating for investment [4].

Core Viewpoint - Kangzheng Pharmaceutical (00867) has received approval from the National Medical Products Administration (NMPA) for clinical trials of its innovative drug CMS-D017, which is aimed at treating complement-mediated kidney diseases [1][2]. Group 1: Drug Development - CMS-D017 is a novel selective complement factor B small molecule inhibitor that targets the complement system, a crucial part of the innate immune system [2]. - The drug aims to prevent abnormal activation of the complement pathway, thereby reducing damage to target tissues and organs associated with complement dysregulation [2]. - Clinical trials will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CMS-D017 in healthy participants in China [1]. Group 2: Indications and Future Development - CMS-D017 is intended for the treatment of various complement-mediated kidney diseases, including IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis, and C3 glomerulopathy [2]. - The drug has previously received approval for treating paroxysmal nocturnal hemoglobinuria and is also being developed for age-related macular degeneration and myasthenia gravis [2]. Group 3: Market Position and Strategy - If approved, CMS-D017 will strengthen the company's position in the kidney disease treatment market, complementing its other innovative drugs, such as Vifor (sucroferric oxyhydroxide chewable tablets for CKD hyperphosphatemia) and Daprodustat (for renal anemia) [3]. - The company is actively preparing to initiate clinical trials for CMS-D017, aiming for a swift market launch [4].

Core Viewpoint - Kangzheng Pharmaceutical has received approval from the National Medical Products Administration (NMPA) for clinical trials of its innovative drug CMS-D017, which targets complement-mediated kidney diseases [1][2]. Group 1: Product Overview - CMS-D017 is a novel selective small molecule inhibitor of complement factor B, which plays a crucial role in the complement system, a key component of the innate immune system [2]. - The drug aims to inhibit the abnormal activation of the complement pathway, thereby reducing damage to target tissues and organs associated with complement dysregulation-related diseases [2]. - CMS-D017 has shown excellent efficacy and safety in preclinical studies and is intended for the treatment of various complement-mediated kidney diseases, including IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis, and C3 glomerulopathy [2][3]. Group 2: Clinical Need and Market Potential - Complement-mediated kidney diseases (CMKD) encompass a range of primary and secondary glomerular diseases, with IgA nephropathy and idiopathic membranous nephropathy being prevalent in China [3]. - Current treatment options, such as steroids and immunosuppressants, have significant limitations, including limited efficacy and notable side effects, indicating a substantial unmet clinical need [3]. - Targeting complement factor B is considered an effective therapeutic approach for CMKD, and CMS-D017 may provide a superior treatment option for patients [3]. Group 3: Strategic Implications for the Company - If approved for market launch, CMS-D017 will enhance the company's strength in the kidney disease treatment sector, complementing its other innovative drugs, such as Vifor (for CKD-related hyperphosphatemia) and Dexamethasone (for renal anemia) [4]. - The synergy between CMS-D017 and existing products is expected to improve the company's competitive position and market presence in the nephrology field [4]. - The company is actively preparing to initiate clinical trial work to expedite the product's market entry [5].

Core Viewpoint - Kangzheng Pharmaceutical has received approval from the National Medical Products Administration (NMPA) for clinical trials of its innovative drug CMS-D017, which is a selective complement factor B small molecule inhibitor aimed at treating complement-mediated kidney diseases [1][2]. Group 1: Drug Development - CMS-D017 is designed to inhibit complement factor B, a key component in the complement system that can lead to tissue damage when abnormally activated [2]. - The drug has shown excellent efficacy and safety in preclinical studies and is intended for conditions such as IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis, and C3 glomerulopathy [2]. - CMS-D017 previously received clinical trial approval for treating paroxysmal nocturnal hemoglobinuria on January 30, 2026, indicating its potential for multiple therapeutic applications [2]. Group 2: Market Position and Strategy - If approved for market launch, CMS-D017 will strengthen the company's position in the kidney disease treatment sector, complementing its other innovative drugs, such as Vifor (for CKD hyperphosphatemia) and Dexamethasone (for renal anemia) [3]. - The company is actively preparing to initiate clinical trials for CMS-D017, aiming for a swift market introduction [4].